Perampanel Study 207: Long-term open-label evaluation in patients with epilepsy

I. Rektor, G. L. Krauss, M. Bar, V. Biton, J. A. Klapper, N. Vaiciene-Magistris, R. Kuba, D. Squillacote, M. Gee, D. Kumar

Research output: Contribution to journalArticlepeer-review


Objectives: Evaluate interim long-term tolerability, safety and efficacy of adjunctive perampanel, a novel α-amino-3-hydroxy-5-methyl-5-isoxazolepropionic acid (AMPA)-receptor antagonist, in patients with refractory partial-onset seizures. Materials and methods: Study 207, an open-label extension (OLE) study ( identifier: NCT00368472), enrolled patients (18-70 years) who completed one of two randomized, placebo-controlled, dose-escalation Phase II studies. The OLE Treatment Phase comprised a 12-week Titration Period (2 mg increments of perampanel every 2 weeks to 12 mg/day, maximum) and a Maintenance Period, during which patients continued treatment up to a planned maximum of 424 weeks (~8 years). Interim analysis data cut-off date was 1 December, 2010. Results: Of 180 patients completing the Phase II studies, 138 enrolled in study 207. At the time of interim analyses (approximately 4 years after study start), over a third (n = 53, 38.4%) remained on perampanel; 41.3% (n = 57) of patients had >3 years of exposure; and 13.0% (n = 18) had at least 4 years' exposure. Mean ± standard deviation (SD) duration of exposure was 116 ± 75 weeks and mean ± SD dose during the OLE Maintenance Period was 7.3 ± 3.3 mg. No new safety signals emerged with long-term treatment. Consistent with previous studies, the most common treatment-emergent adverse events were as follows: dizziness, headache and somnolence. Overall median (range) per cent change from baseline in seizure frequency per 28 days during open-label treatment was -31.5% (-99.2 to 512.2). Conclusions: Long-term - up to 4 years - adjunctive perampanel had a favourable tolerability profile in patients with refractory partial-onset seizures. Improvements in seizure control were maintained with long-term treatment.

Original languageEnglish (US)
Pages (from-to)263-269
Number of pages7
JournalActa Neurologica Scandinavica
Issue number4
StatePublished - Oct 2012


  • Antiepileptic drugs
  • Epilepsy
  • Glutamate
  • Long-term safety
  • Open-label extension
  • Perampanel
  • Post-synaptic
  • α-amino-3-hydroxy-5-methyl-5-isoxazolepropionic acid

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Perampanel Study 207: Long-term open-label evaluation in patients with epilepsy'. Together they form a unique fingerprint.

Cite this